AMPH Amphastar Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: AMPH
Price (delayed)
$30.48
Market cap
$1.42B
P/E Ratio
10.85
Dividend/share
N/A
EPS
$2.81
Enterprise value
$1.88B
Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active
Highlights
The stock's P/E is 85% less than its 5-year quarterly average of 73.1 and 2.3% less than its last 4 quarters average of 11.1
Amphastar Pharmaceuticals's equity has increased by 6% YoY
Amphastar Pharmaceuticals's quick ratio has decreased by 19% YoY but it has increased by 8% QoQ
The net income has contracted by 19% YoY and by 4.9% from the previous quarter
The EPS has contracted by 18% YoY and by 3.8% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.amphastar.com
Peers:
SCYX
Key stats
What are the main financial stats of AMPH
Market
Valuations
Earnings
Shares outstanding
46.5M
Market cap
$1.42B
Enterprise value
$1.88B
Price to earnings (P/E)
10.85
Price to book (P/B)
1.9
Price to sales (P/S)
1.98
EV/EBIT
10.05
EV/EBITDA
7.24
EV/Sales
2.61
Revenue
$722.68M
Gross profit
$360.33M
Operating income
$181.67M
Net income
$134.71M
EBIT
$187.53M
EBITDA
$260.44M
Free cash flow
$112.19M
Per share
Balance sheet
Liquidity
EPS
$2.81
EPS diluted
$2.67
Free cash flow per share
$2.39
Book value per share
$16.07
Revenue per share
$15.39
TBVPS
$22.08
Total assets
$1.62B
Total liabilities
$857.85M
Debt
$655.5M
Equity
$757.48M
Working capital
$404.42M
Debt to equity
0.87
Current ratio
3.29
Quick ratio
2.08
Net debt/EBITDA
1.8
Margins
Efficiency
Dividend
EBITDA margin
36%
Gross margin
49.9%
Net margin
18.6%
Operating margin
25.1%
Return on assets
8.5%
Return on equity
18.2%
Return on invested capital
14.5%
Return on capital employed
13%
Return on sales
25.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AMPH stock price
How has the Amphastar Pharmaceuticals stock price performed over time
Intraday
0.43%
1 week
46.4%
1 month
40.72%
1 year
-30.03%
YTD
-17.91%
QTD
32.75%
Financial performance
How have Amphastar Pharmaceuticals's revenue and profit performed over time
Revenue
$722.68M
Gross profit
$360.33M
Operating income
$181.67M
Net income
$134.71M
Gross margin
49.9%
Net margin
18.6%
AMPH's operating margin is down by 22% year-on-year and by 6% since the previous quarter
AMPH's net margin is down by 21% year-on-year and by 4.1% since the previous quarter
The operating income has declined by 21% year-on-year and by 7% since the previous quarter
The net income has contracted by 19% YoY and by 4.9% from the previous quarter
Price vs fundamentals
How does AMPH's price correlate with its fundamentals
Growth
What is Amphastar Pharmaceuticals's growth rate over time
Valuation
What is Amphastar Pharmaceuticals stock price valuation
P/E
10.85
P/B
1.9
P/S
1.98
EV/EBIT
10.05
EV/EBITDA
7.24
EV/Sales
2.61
The stock's P/E is 85% less than its 5-year quarterly average of 73.1 and 2.3% less than its last 4 quarters average of 11.1
The EPS has contracted by 18% YoY and by 3.8% from the previous quarter
The price to book (P/B) is 34% lower than the 5-year quarterly average of 2.9 and 14% lower than the last 4 quarters average of 2.2
Amphastar Pharmaceuticals's equity has increased by 6% YoY
AMPH's price to sales (P/S) is 34% less than its 5-year quarterly average of 3.0 and 14% less than its last 4 quarters average of 2.3
Efficiency
How efficient is Amphastar Pharmaceuticals business performance
The ROIC is down by 32% year-on-year and by 9% since the previous quarter
The ROE has contracted by 28% YoY and by 6% from the previous quarter
The ROS has contracted by 24% YoY and by 6% from the previous quarter
The company's return on assets fell by 22% YoY and by 7% QoQ
Dividends
What is AMPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AMPH.
Financial health
How did Amphastar Pharmaceuticals financials performed over time
The total assets is 88% greater than the total liabilities
Amphastar Pharmaceuticals's quick ratio has decreased by 19% YoY but it has increased by 8% QoQ
Amphastar Pharmaceuticals's current ratio has increased by 12% from the previous quarter but it has decreased by 7% YoY
AMPH's debt is 13% smaller than its equity
Amphastar Pharmaceuticals's equity has increased by 6% YoY
AMPH's debt is up by 6% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.